Claris gets USFDA nod to market Furosemide injection

Claris Lifesciences has received US health regulator's nod to market Furosemide injection, used to treat fluid retention, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for Furosemide injection in different package sizes, Claris Lifesciences Ltd said in a filing to the BSE.
Furosemide is used to treat edema (fluid retention) that occurs with congestive heart failure and disorders of the liver, kidney and lung, it added.
The drug is also used to mild to moderate blood pressure.
"The product has been facing supply issues in the US during the past year on various occasions and has also featured in the USFDA shortage list since June 2012," Claris said.

Claris Lifesciences shares closed at Rs 177.65 apiece on the BSE, down 0.53 per cent from its previous close.